Summary sheet
The project consists of a quasi-equity loan to Greenbone, an Italian medtech company developing innovative bone-regenerating implants and bone replacement solutions to treat severe fractures and conditions, such as trauma and tumours causing extensive bone loss.
The aim is to finance the company's research, development and innovation (RDI) and costs scale up.
The promoter is a European R&D company specialised in development of an advance material for bone substitution. In addition to its own RDI capabilities, the promoter has developed a well-established network of collaborations with universities, research institutions and reputed industry partners. Companies producing innovative high quality products are key drivers of economic growth, productivity and social protection, and generally a source of high value added employment. The EIB support to this operation is expected to provide tangible value-added benefit, positively contributing to the promoter's R&D investments by lowering the associated cost of financing and offering loan maturity beyond the tenor usually offered by commercial banks as well as disbursement mechanics more suitable for the project's financing and more flexible than those normally proposed by the market.
The promoter's investment concerns RDI activities expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an Environmental Impact Assessment (EIA) under Directive 2011/92/EU. Full environmental details will be verified during appraisal.
The promoter is a private company, not operating in the utilities sector and not having the status of a contracting authority. Therefore, the EU directives on procurement are not applicable. Nevertheless, the promoter's procurement procedures are expected to be in line with the EIB's guidelines for private sector projects. Further details will be verified during the project due diligence.